Using Dual SGLT Inhibitors to Treat Heart Failure
Monograph
Are you a Pharmacy Tech? Check out the Pharmacy Tech version of this course.
Course Summary
Heart failure, a complex and prevalent cardiovascular condition, presents challenges and opportunities for healthcare providers. Dual SGLT2 inhibitors provide a newer option for heart failure management. This course discusses the mechanisms of action, clinical evidence, and patient selection criteria applicable to the use of dual SGLT2 inhibitors. The pharmacist, supported by pharmacy staff, has a role in patient education and care coordination in heart failure management.
Course Objectives
Summarize the potential effectiveness of using dual SGLT inhibitors in heart failure management
Review the mechanism of action of sotagliflozin
Describe the warnings and precautions for the use of sotagliflozin
Recognize potential adverse events associated with the use of dual SGLT inhibitors
I. Introduction
II. Dual Sodium-Glucose Cotransporter Inhibitors
III. Prevalence and Risk Factors for Heart Failure
IV. Dual SGLT Inhibitors
V. Sotagliflozin’s Clinical Trials
VI. Sotagliflozin’s Mechanism of Action
VII. Indications for Sotagliflozin
VIII. Dosing for Sotagliflozin
IX. Sotagliflozin’s Side Effects or Adverse Events
X. Drug-Drug Interactions
XI. Handling and Storage of Sotagliflozin
XII. Sotagliflozin and Special Populations
1. Surgical Patients
2. Diabetic Ketoacidosis (DKA)
3. Volume Depletion
4. Pregnancy
5. Lactation
6. Pediatric
7. Geriatric
8. Renal Impairment
9. Hepatic Impairment
XIII. Future Trends
XIV. Patient Counseling
XV. Summary
- Read the course objectives and faculty planner disclosure
- Read the course material
- Complete the post-test with a minimum score of 70% and complete the course evaluation form.
- Results are automatically submitted to CPE Monitor
Faculty Planner Disclosure
The following individuals were involved in developing this activity: Steven Malen, PharmD, MBA, and Pamela Sardo, PharmD, BS. Pamela Sardo was an employee of Rhythm Pharmaceuticals until March 2022 and has no conflicts of interest or relationships regarding the subject matter discussed. There are no financial relationships relevant to this activity to report or disclose by any of the individuals involved in the development of this activity.
Unlabeled Use Disclosures
The information provided in this course is general in nature and it is solely designed to provide participants with continuing education credit(s). This course and materials are not meant to substitute for the independent, professional judgment of any participant regarding that participant’s professional practice, including but not limited to patient assessment, diagnosis, treatment and/or health management. Medical and pharmacy practices, rules, and laws vary from state to state, and this course does not cover the laws of each state; therefore, participants must consult the laws of their state as they relate to their professional practice. Healthcare professionals, including pharmacists and pharmacy technicians, must consult with their employer, healthcare facility, hospital, or other organization, for guidelines, protocols, and procedures they are to follow. The information provided in this course does not replace those guidelines, protocols, and procedures but is for academic purposes only, and this course’s limited purpose is for the completion of continuing education credits. Participants are advised and acknowledge that information related to medications, their administration, dosing, contraindications, adverse reactions, interactions, warnings, precautions, or accepted uses are constantly changing, and any person taking this course understands that such person must make an independent review of medication information prior to any patient assessment, diagnosis, treatment and/or health management. Any discussion of off-label use of any medication, device, or procedure is informational only and such uses are not endorsed hereby. Nothing contained in this course represents the opinions, views, judgments, or conclusions of RxCe.com LLC. RxCe.com LLC is not liable or responsible to any person for any inaccuracy, error, or omission with respect to this course, or course material.
Computer Hardware/Software Requirements
Please ensure the device you plan to use meets these requirements and specifications:
- Operating System: Windows 7,8,10, or 11 /Mac OS X 10.9 or later/iOS/Android
- Supported Browsers: Microsoft Edge, Firefox, Google Chrome, Safari, Opera
- A connection to the internet
- For Live Webinars or Conferences: GoToWebinar application for iOS, Android, Mac, or PC. You cannot 'call into' a live conference.
Rating: 4.91/5
Based on the ratings of 45 customers
- Target Audience: Pharmacist
- Contact Hours: 1.0 (0.1 CEUs)
- Activity Release Date: 10/27/2023
- Activity Expiration Date: 10/27/2026
- Activity Type: Knowledge
- UAN: 0669-0000-23-180-H01-P
- Topic: Disease State Management/Drug Therapy
- CeBroker Number: 20-1120874
Author:
RxCe.com, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.